Compare Lloyds Banking Group Plc American Depositary Shares (LYG) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lloyds Banking Group Plc American Depositary Shares vs Travere Therapeutics Inc. Common Stock — how do they compare? Lloyds Banking Group Plc American Depositary Shares trades at $5.48 (market cap $79.07B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Lloyds Banking Group Plc American Depositary Shares is far larger — about 16.2× Travere Therapeutics Inc. Common Stock's market cap, and Lloyds Banking Group Plc American Depositary Shares pays a 3.96% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lloyds Banking Group Plc American Depositary Shares for 3 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| LYG | TVTX | |
|---|---|---|
Market Cap | $79.07B | $4.88B |
Volume | 20,385,611 | 1,668,577 |
Sector | Financials | Health |
52-Week High | $6.28 | $67.52 |
52-Week Low | $4.44 | $26.79 |
Typical Hold Time | 3 Days | 0 Days |
Enterprise Value | $101.61B | $5.01B |
Dividend Yield | 3.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lloyds Banking Group (LYG) trades at $5.50, up 0.73% on the day, with a bearish technical signal from moving averages. The company reported strong profitability with a net income margin of 24.5% and has beaten earnings estimates in two of the last three quarters. Recent news highlights its 2030 growth plan emphasizing AI and efficiency, with potential acquisition interest in Aldermore.
The outlook is mixed: analyst consensus is bullish (58% buy ratings), but technicals and a recent earnings miss pose near-term risks. Upside catalysts include strategic investments and resilient UK consumers, while risks involve economic sensitivity and competitive pressures. The stock's valuation appears reasonable with a P/E of 12.98.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Lloyds Banking Group Plc American Depositary Shares
Lloyds Banking Group provides retail, commercial, and insurance services in the United Kingdom. Its banking brands include Lloyds Bank, Halifax, and Bank of Scotland.
Read more on LYG →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
